REG
Kallelse till årsstämma i Coegin Pharma AB (publ)
Aktieägarna i Coegin Pharma AB kallas härmed till årsstämma torsdagen den 21 maj 2026 kl. 10.00 på Medicon Village, Scheeletorget 1, i Lund.
Rätt att delta och anmälan Aktieägare...
REG
Notice of annual general meeting in Coegin Pharma AB (publ)
The shareholders of Coegin Pharma AB are hereby invited to attend the Annual General Meeting on Thursday, 21 May 2026 at 10:00 a.m. at Medicon Village, Scheeletorget 1, Lund.
Rig...
Coegin Pharma expands commercial strategy with own-brand distribution model - launches VEXIENNE®
Coegin Pharma AB ("Coegin" or the "Company") today announces the expansion of its commercial strategy through the introduction of an own-brand distribution model for its Follicop...
Coegin Pharma's management acquires shares in the company
Coegin Pharma AB today announces that the company's CEO, CFO and CMO have acquired additional shares in the company.
CEO Jens Eriksson has acquired 24,293 shares, CFO Lars Bukhav...
Coegin Pharma receives first purchase order for new scalp serum
Coegin Pharma AB ("Coegin" or the "Company") today announces that it has received its first limited purchase order for the Company's newly introduced high-performance cosmetic sc...
Coegin Pharma accelerates Follicopeptide® portfolio expansion with a new high-performance scalp serum
Coegin Pharma AB ("Coegin") today announces further details on the launch of a new high-performance cosmetic scalp serum developed to optimize the scalp environment. The product...
REG
Coegin Pharma AB (publ) publishes its year-end report for 2025
Summary of year-end report 2025With products on the market, strengthened financing and a growing platform strategy, Coegin Pharma enters 2026 from a significantly stronger positi...
REG
MAR
Coegin Pharma carries out directed issues totalling approx. SEK 12.1 million and strengthens the Company's liquidity position
The Board of Directors of Coegin Pharma AB (publ) (the "Company" or "Coegin Pharma") has today resolved to carry out directed issues totalling up to approximately SEK 12.1 millio...
Coegin Pharma provides an operational and strategic update
Coegin Pharma AB ("Coegin" or the "Company") today provides an operational and strategic update regarding its commercialization activities and business planning.
Operational upda...
Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor
Coegin Pharma AB ("Coegin") is delighted to announce that Professor Desmond J. Tobin, a globally recognized leader in skin and hair pigmentation science and hair-follicle biology...
Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken
Coegin Pharma AB ("Coegin" or the "Company") today announces that the Company has completed its first commercial delivery of hair growth products based on Follicopeptide® to Hårk...
Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents
Coegin Pharma AB ("Coegin" or the "Company") today announces that the Company has successfully produced and delivered its first commercial batch of hair growth products based on...
REG
Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting
The Nomination Committee of Coegin Pharma has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on May 22, 2025....
REG
Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025
Summary of interim reportThe third quarter of 2025 marks a historic turning point for Coegin Pharma. The company has successfully transitioned from a development-focused biotech...
First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma
Coegin Pharma AB ("Coegin" or "the Company") is proud to announce that starting November 16, customers can pre-order Gents Power Hair Activating Formula through Gents' online sto...
Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026
Coegin Pharma AB ("Coegin" or "the Company") announces that it has finalized the development of a new, tailor-made Follicopeptide complementary product. It is designed to strengt...
REG
MAR
Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand
Coegin Pharma AB ("Coegin" or "the Company") has entered a collaboration with Hårklinikken, a global actor in premium, science-driven hair and scalp health, through the signing o...
Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth
Coegin Pharma AB ("Coegin" or "the Company") provides a status update about the establishment of its own agile production facility in Denmark. It enables the Company to secure fu...
Om Coegin Pharma
Coegin Pharma är ett svenskt innovationsbolag som utvecklar och kommersialiserar avancerade kosmetiska teknologier för hår och hud.
Webbplats
www.coeginpharma.com
Bransch
Bioteknik
Prenumerera
Få löpande information från Coegin Pharma via e-post.
Handelsinformation
Kurs 4,2 SEK (2026-04-21)
Förändring −2,1% (2025-04-17)